EUCTR2006-004467-65-DE进行中（未招募）不适用
Influence of pioglitazone for renal transplant function in diabetics
Technical University Dresden0 个研究点开始时间: 2006年10月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-renal transplant recipient (> 6 months after renal transplantation) with stable renal function (fluctuations of serum creatinin < 20% within 3 months prior to the screening examination)
- •-age between 30 and 75 years
- •-type 2 diabetes mellitus with acceptable glycemic control (HbA1c < 8%)
- •-estimated GFR >30 ml/min (MDRD formula)
- •-albuminuria > 30 mg / day
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- type 1 diabetes mellitus
- •- HbA1c > 8 %
- •- unstable renal function (any acute rejection episode within 3 months prior to the screening or chronic allograft nephropathy with fluctuation of serum creatinin > 20 %)
- •- pregnant or breastfeeeding women
- •- congestive heart failure > stage 1 NYHA
- •- uncontrolled hypertension
- •- hypo- or hyperthyreoidism
研究者
相似试验
已完成
3 期
Influence of Pioglitazone for Renal Transplant Function in DiabeticsKidney TransplantationProteinuriaDiabetes MellitusNCT00507494Technische Universität Dresden
已完成
不适用
Effect of pioglitazone on renal function amelioration by measurement of cystatine C levels in the type 2 diabetic patientsDiabetic nephropathyJPRN-UMIN000000689Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine70
已完成
不适用
Therapeutic effect of pioglitazone on chronic kidney disease (CKD).JPRN-UMIN000001017ational Defense Medical College24
进行中（未招募）
不适用
Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and an activated inflammationA randomized double-blinded phase II studyon-diabetic hypertensive patients with a hsCRP value > 1.0 mg/L < 10.0 mg/L and pretreated with ACE inhibitors for at least 12 weeks are eligible for study participation.MedDRA version: 8.1Level: LLTClassification code 10003601Term: AtherosclerosisEUCTR2006-004028-35-DETakeda Pharma GmbH
Unknown
4 期
Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRDESRDNCT01253928Centre Hospitalier Universitaire Vaudois16